GLP-1R Actions on Muscle and the Skeleton
NCT07154719 on ClinicalTrials.gov · last registry update 2026-08-27
Recruiting now, toward 50 participants. Due to report 1 February 2027. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.
- Status
- RECRUITING
- Phase
- P4
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- Pennington Biomedical Research Center
- Sponsor type
- Other
- Enrollment
- 50
- Started
- 2025-10-09
- Primary completion
- 2027-02-01 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-08-27 | Status changed | ACTIVE_NOT_RECRUITING → RECRUITING |
Primary outcome
Changes in fat free mass (FFM) using DXA imaging. FFM equals all body composition that is not fat mass. This includes bone, skeletal muscle, organs, water and all connective tissues. The unit of measurement is in kilograms (kg) at baseline, 3 and 6 mo.
Conditions studied
Musculoskeletal Abnormalities · Obesity · Sarcopenic Obesity · Osteoporosis · Drug Effect
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.